Ebronucimab in Chinese patients with hypercholesterolemia---A randomized double-blind placebo-controlled phase 3 trial to evaluate the efficacy and safety of ebronucimab

Ebronucimab in Chinese patients with hypercholesterolemia---A randomized double-blind placebo-controlled phase 3 trial to evaluate the efficacy and safety of ebronucimab

Randomized clinical trials (RCTs) of PCSK9 monoclonal antibody(mAb) specifically for Chinese patients have been limited. This multi-center RCT is to clarify the efficacy and safety of a novel mAb, Ebronucimab, in Chinese patients. Patients diagnosed with primary hypercholesterolemia, including Heter...

Full description

Bibliographic Details
Main Authors: Yanyan Zhang, Zhaohui Pei, Beijian Chen, Yanling Qu, Xiaolin Dong, Binge Yu, Guoqin Wang, Fang Xu, Dongmei Lu, Zhimei He, Benchao Chen, Lei Ma, Max Wang, Baiyong Li, Michelle Xia, Bo Zheng, Yong Huo
Format: Article
Language:English
Published: Elsevier 2024-09-01
Series:Pharmacological Research
Subjects:
Ebronucimab
Proprotein convertase subtilisin/Kexin Type 9 monoclonal antibody
Low-density lipoprotein cholesterol
Atherosclerotic cardiovascular disease
Online Access:http://www.sciencedirect.com/science/article/pii/S1043661824002858

Internet

http://www.sciencedirect.com/science/article/pii/S1043661824002858

Similar Items